Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Files Patent Infringement Suit Against Affymetrix

NEW YORK (GenomeWeb News) – Illumina has filed a lawsuit against Affymetrix alleging infringement its array technology.

The suit, filed yesterday in the US District Court for the Western District of Wisconsin, alleges that a variety of Affymetrix products infringe Illumina's US Patent No. 7,510,841, entitled, "Methods of Making and Using Composite Arrays for the Detection of a Plurality of Target Analytes." The patent was issued on March 31, 2009.

The Affy products named in the suit include the GeneChip HT RG-230 PM Array Plate, the GeneChip HT Array Plate Scanner, the GeneChip HT 3' IVT Express Kit, the GeneChip Array Station, and the GeneTitan Institute.

Illumina is seeking a judgment from the court that Affy has indirectly and directly infringed one or more of the claims of the '841 patent and that each of the claims of the patent are valid and enforceable. It also seeks a permanent injunction barring Affy from making and selling the named products, as well as a judgment that Affy has willfully infringed the '841 patent and should pay triple damages as a result.

In a filing with US Securities and Exchange Commission on Monday, Affy said that it believes Illumina's claims are without merit and that it will "vigorously defend against them."

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.